TherapeuticsMD, Inc. (TXMD)

Every figure this model derived for TXMD, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2022-09-30
cash 9,189,000 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2026-06-30
current assets 16,121,000 AssetsCurrent 2026-06-30
current liabilities 5,003,000 LiabilitiesCurrent 2026-06-30
equity 27,132,000 StockholdersEquity 2026-06-30
interest expense 8,000 InterestExpenseDebt 2025-12-31
ocf 3,097,000 NetCashProvidedByUsedInOperatingActivitiesContinuingOperations 2026-06-30
revenue 3,270,000 RevenueFromContractWithCustomerIncludingAssessedTax 2026-06-30
sbc 57,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TXMD on one particular measure came for.

RatioValue
cash operating margin-107.46
current ratio3.22
current ratio reported3.22
dilution pct0.32
fcf margin94.71
growth cv2.09
interest cover-494.12
operating margin-120.89
owner earnings margin92.97
revenue growth27.78
revenue growth per share27.38
roic-17.4
rule of 40-93.1
sbc pct revenue1.74

What to be careful about

What this model itself distrusts about TXMD's figures. Written by the derivation as it ran, not added afterwards.